Johnson & Johnson and Lupin will supply their versions of the tuberculosis drug bedaquiline at a significantly cheaper price in low- and middle-income countries, according to the Stop TB Partnership. The new prices, $130 for J&J and $194 for Lupin for a six-month course of treatment, represent a 55% and 33% reduction, respectively. Bedaquiline is a key part of recommended treatment regimens for drug-resistant TB infections, and this price reduction will help broaden access to the life-saving drug.
